Original article published in Newsweek on November 5th, 2021. Written by the Worldfolio

CMIC: Japan’s premier personal health value creator
CMIC Group is the largest clinical CRO in Japan, providing comprehensive services in drug development, clinical sitemanagement, clinical to commercial GMP manufacturing, and contract sales & marketing solutions. CMIC not only
provides services spanning the entire pharmaceutical value chain, but also invests in solutions to support healthcare.

As the world’s third largest pharmaceutical market with progressive
healthcare policies that allow for theaccelerated approval of innovative
drugs, Japan remains a very attractive market for foreign companies.
The first company to offer contract

thorities and our clients. We provide
unique solutions for pharmaceuticalcompanies along their entire drug
development value chain.”Over the past 30 years, CMIC
has expanded its range of highquality services to encompass theentire pharmaceutical value chain,and today is composed of 24 affiliated companies mostly operatingin the fields of CRO, Site Management Organization (SMO), Contract
Development and Manufacturing
Organization (CDMO) and Contract
Sales Organization (CSO). With
its growing network of overseas
subsidiaries, CMIC can also support
companies targeting the Chinese,
South Korean and fast-growing
Southeast Asian markets.
“Having multiple functional service providers creates a numberof synergistic effects. For example,
there are many collaborative projects between non-clinical organizations and CDMO,” says Ms. Oishi.
“This can lead to a smooth projecttransition to gain speed and potential
reduction in cost for our clients. Thislevel of teamwork between our companies and clients also allows us tohave discussions on critical issues like
CMC quality issues which can help
avoid delays in clinical trial timelines.”
Still channeling the pioneering
spirit that led the company to become the first CRO service pro-research organization (CRO) services
in Japan almost 30 years ago, CMICGroup can serve as the ideal partner
for foreign companies looking for aleading one-stop service provider
to support their entry and successful growth in the Japanese market,
from pre-clinical and clinical trials,
to approval, and sales & marketing.
“We provide an invaluable service
to foreign companies wishing tocome to Japan,” says president,
Keiko Oishi. “CMIC helps clients toshorten their overall timelines as wework very closely with both the au-vider almost 30 years ago, CMIC isleading the change when it comesto digital transformation within
the healthcare industry. In October, it established a new company
called harmo Co., Ltd., which will
be responsible for the digital platform services of the harmo brand,
including its electronic prescription record system and its vaccine
information management system.
With the harmo digital platform,
CMIC will be able to collect large
streams of valuable data onsitethat will be used to provide tailored“CMIC will accelerate
globalization with its
network and experiencein Asia to enhance
global trials capabilities.
Healthcare will becomea major focus for us
over the next four years
as we broaden oursolutions beyond thepharmaceutical industry.”
Keiko Oishi, President,
CMIC HOLDINGS CO., LTD.

analysis and essential information
for clients, as well as individuals andlocal governments. “We describe
the product as a ‘communication echannel’,” Ms. Oishi explains. “Overthe next couple of years, we expect
harmo to rise as a leading digitaltechnology platform, creating a
new and unique type of company
within CMIC Group.”
In response to changing market
and societal needs, CMIC has transitioned its business model from Pharmaceutical Value Creator (PVC) toPersonal Healthcare Value Creator(PHVC). And this is the core of its
strategic pillars, along with the revo-lution of healthcare and globalization.
“In terms of globalization, there
are foreign companies from the USand Europe that are very interested
in selling or marketing their products
here in Japan and some new trials
brought in through our inward projects are now increasing. CMIC is a
strategic partner that continues tosupport our clients’ market accessand expansion of product values inJapan,” says Ms. Oishi. “Meanwhile,healthcare will become a major focus for us over the next four years
as we shift our focus beyond thepharmaceutical industry. This will bea challenging but exciting journey.”PERSONAL HEALTH VALUE CREATOR (PHVC)
CMIC Group pioneered the CRO business in Japan 30 years
ago. Since then CMIC has continued as a leading innovatorin the industry, with broadened services spanning theentire pharmaceutical value chain and investment insolutions to support healthcare.

https://en.cmicgroup.com